Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02791243
Other study ID # PM1542
Secondary ID
Status Completed
Phase Phase 1
First received June 1, 2016
Last updated May 17, 2017
Start date May 9, 2016
Est. completion date June 27, 2016

Study information

Verified date May 2017
Source Polichem S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)


Description:

Healthy male volunteers, drawn from the general population, will be treated with P-3074 solution, placebo vehicle control and 0.9% sodium chloride USP (negative control) by using 6 induction applications on the back area and Ultraviolet A (UVA)/Ultraviolet B (UVB) irradiations during the 3 week induction period, a 10 day rest period, and a challenge phase of a 24-hour patch application, UVA and UVB irradiation followed by evaluation of photosensitization over the subsequent 72 hours.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date June 27, 2016
Est. primary completion date June 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Males aged 18 to 65.

2. Good general health, as assessed by verbal medical history and brief physical examination of the skin.

3. Fitzpatrick Skin Type I-IV, determined by interview at screening.

4. Willing to use a double-barrier methods (for example, a condom or a diaphragm plus spermicide) during sexual intercourse with a female partner while participating in the study.

5. Male subjects will need to confirm method and length of time for method of birth control for female partners.

6. Fully informed of the risks of entering the study and willing to provide written consent to enter the study.

7. Willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area

8. Must be willing not to change current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating on the study.

Exclusion Criteria:

1. MED = 2.5 SED for Fitzpatrick Skin Types I and II or MED = 4.0 SED for Fitzpatrick Skin Types III and IV

2. Type I Insulin-dependent diabetes

3. Mastectomy for cancer involving removal of lymph nodes draining the test site.

4. Clinically significant skin diseases which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active skin cancer.

5. Use of any photosensitizing medications or supplements, such as but not limited to sulfa drugs, tetracyclines, phenothiazines, thiazides, antiemetics and St. John's Wort.

6. Any medical conditions caused or affected by sunlight (UV), such as but not limited to solar urticarial and polymorphous light eruptions.

7. Active immunologic disorders.

8. Routine use of anti-inflammatory, immunosuppressive or antihistamine medications (81 mg aspirin is acceptable).

9. Participation in a patch test or soap chamber test within the past 4 weeks.

10. History of significant sensitivity or allergy to adhesive bandages, tapes, etc.

11. Use of finasteride (oral and/or topical), within 6 months prior to the screening visit.

12. Contraindications to finasteride therapy or intolerance of finasteride.

13. History of sensitivity to skin solution products.

14. Hair, tattoos, pigmentation, scars, moles or other conditions at the areas to be patched that may interfere with patch application, tolerability, or postapplication evaluations.

15. Participation in a clinical trial or receipt of an investigational medication within 4 weeks of the study.

16. Current treatment with allergy injections.

17. History of severe asthma.

18. Chronic or active liver disease [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5x upper limit of normal (ULN)]

19. Neutrophils < 1500 cells/mm3

20. Clinically significant chronic illness, which could place the subject at increased risk during participation or result in inappropriate dermal response during the study in the opinion of the Investigator.

21. History of alcohol or drug abuse within 1 year of the study.

22. Any condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk.

23. Judged by the investigator to be unsuitable for any reason.

Study Design


Intervention

Drug:
Finasteride 0.25%
Cutaneous solution of finasteride 0.25%
Placebo for Finasteride 0.25%
vehicle cutaneous solution of P-3074
Negative Control
0.9% aqueous NaCl

Locations

Country Name City State
United Kingdom Princeton Consumer Research Inc. Chelmsford, Essex

Sponsors (1)

Lead Sponsor Collaborator
Polichem S.A.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Potential for induction of photosensitization from day 4 to day 42
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A